Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB4-845 in BCG-unresponsive NMIBC (China)
CTR20210648Phase 3Terminated
- Sponsor
- Sesen Bio
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of oportuzumab monatox in non-muscle-invasive bladder cancer (NMIBC), sponsored by Sesen Bio. Started Mar 2021; status: terminated.
02
Drugs
oportuzumab monatox
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20210648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210648.